Daniele
Fri Nov 01 2024
|
5 answers
1225
What are JAK inhibitors for STAT1 GOF?
JAK inhibitors are drugs that target the JAK-STAT signaling pathway, which is involved in various immune and inflammatory responses. In the context of STAT1 GOF (gain-of-function) mutations, JAK inhibitors such as ruxolitinib have been shown to effectively reverse immune dysregulation by reducing hyperphosphorylation of STAT1 and preventing excessive T-cell apoptosis. This suggests that JAK inhibitors could be a potential therapeutic option for patients with STAT1 GOF-related conditions.
